Analysis of peripheral tolerance in vivo
体内外周耐受性分析
基本信息
- 批准号:8308579
- 负责人:
- 金额:$ 33.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2013-05-14
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdoptive TransferAffinityAntigen-Presenting CellsAntigensAutoantigensAutoimmune DiseasesAutoimmunityCD4 Positive T LymphocytesCell DeathCellsComplexDevelopmentEctopic ExpressionEpithelial CellsEventFemaleGene TargetingGoalsIndividualInflammationLeadLigandsLightLymphoidLymphokinesMagnetismMajor Histocompatibility ComplexMature T-LymphocyteMediatingMethodsModelingMusOrganPeptidesPeripheralPhenotypePhysiologicalPlayPregnancyPrincipal InvestigatorProcessProductionProliferatingProteinsRegulatory T-LymphocyteRoleSeriesSurvivorsT cell anergyT-Cell ReceptorT-LymphocyteTestingThymus GlandTissuesTransgenic Micebasefunctional statusimmunogenicin vivomemberperipheral tolerancepregnantprogramsreceptorresearch studysperm cellsuccesstheoriesthymocytetooltranscription factor
项目摘要
The long-term goal of this project is an understanding of the mechanisms that account for CD4+ T cell
tolerance to antigens that are presented in the secondary lymphoid organs but not the thymus. Previously, we
showed that naive CD4+ T cells that are exposed to model antigens in the secondary lymphoid organs in the
absence of inflammation proliferate poorly, then most of the progeny die, and the survivors enter an anergic
state characterized by poor lymphokine production. The goal of this application is to establish whether or not
a similar series of events accounts for peripheral tolerance to certain natural self-proteins. This has become a
pressing issue since the discovery that the AIRE transcription factor drives ectopic expression of extrathymic
gene products in the thymus. Thus, it remains possible that the physiological role that peripheral tolerance
was thought to play is really played by AIRE-mediated intrathymic tolerance. Here, we will test the hypothesis
that peripheral tolerance is physiologically-relevant by using new tools to identify the tolerance mechanisms
that apply to two pregnancy-specific proteins, one that appears to be regulated by AIRE and another that
does not, and one sperm-specific protein. We will determine whether or not these proteins are immunogenic
in mice that have never expressed them in the relevant tissue (e.g., non-pregnant female mice), and become
non-immunogenic in mice after expression (e.g., pregnant female mice). The relevant antigenic peptides will
be identified and used to produce peptide-MHC II multimers. The multimers will then be used with a sensitive
new enrichment method capable of detecting fewer than 100 cells per mouse to enumerate peptide MHC II-
specific CD4+ T cells before, during, and after expression of the relevant protein within the polyclonal
repertoires of normal mice. This approach should reveal whether or not the relevant CD4+ T cells are deleted,
turn into regulatory cells, or become anergic during or after the period when these developmental^ regulated
self-proteins are expressed. This approach will then be used in gene-targeted mice to determine whether or
not molecules such as Fas and Cbl-b, and others identified by other members of the P01, are involved in the
identified tolerance mechanism. Success would provide the first definitive identification of the peripheral
tolerance mechanism that applies to a natural self-antigen. This information should help focus future research
on the relevant mechanism and shed light on the potential ways that it could fail and lead to autoimmunity.
该项目的长期目标是了解 CD4+ T 细胞的机制
对次级淋巴器官而非胸腺中存在的抗原具有耐受性。此前,我们
研究表明,暴露于次级淋巴器官中模型抗原的初始 CD4+ T 细胞
没有炎症,增殖不良,然后大多数后代死亡,幸存者进入无反应状态
淋巴因子产生不良的状态。该应用程序的目标是确定是否
一系列类似的事件解释了外周对某些天然自身蛋白的耐受性。这已经成为一个
自从发现 AIRE 转录因子驱动胸腺外异位表达以来,这是一个紧迫的问题
胸腺中的基因产物。因此,外周耐受性的生理作用仍然是可能的。
被认为发挥的作用实际上是由AIRE介导的胸腺内耐受发挥的。在这里,我们将检验假设
通过使用新工具来识别耐受机制,外周耐受具有生理相关性
适用于两种妊娠特异性蛋白质,一种似乎受 AIRE 调节,另一种则受 AIRE 调节
不,还有一种精子特异性蛋白质。我们将确定这些蛋白质是否具有免疫原性
在从未在相关组织中表达过它们的小鼠(例如,未怀孕的雌性小鼠)中,并成为
表达后对小鼠(例如怀孕的雌性小鼠)无免疫原性。相关的抗原肽将
被鉴定并用于生产肽-MHC II 多聚体。然后多聚体将与敏感的
新的富集方法能够检测每只小鼠少于 100 个细胞来计数肽 MHC II-
多克隆内相关蛋白表达之前、期间和之后的特异性 CD4+ T 细胞
正常小鼠的曲目。这种方法应该揭示相关的 CD4+ T 细胞是否被删除,
转变为调节细胞,或者在这些发育^调节期间或之后变得无能
自身蛋白被表达。然后,该方法将用于基因靶向小鼠,以确定是否或
并非 Fas 和 Cbl-b 等分子以及 P01 其他成员识别的其他分子参与
确定的耐受机制。成功将提供外设的第一个明确识别
适用于天然自身抗原的耐受机制。这些信息应该有助于集中未来的研究
相关机制并阐明其可能失败并导致自身免疫的潜在方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marc Kevin Jenkins其他文献
Marc Kevin Jenkins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marc Kevin Jenkins', 18)}}的其他基金
Detection and Activation of CD4+ T cells with Low Affinity TCRs
低亲和力 TCR 的 CD4 T 细胞的检测和激活
- 批准号:
10348758 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
Detection and Activation of CD4+ T cells with Low Affinity TCRs
低亲和力 TCR 的 CD4 T 细胞的检测和激活
- 批准号:
10570243 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
相似海外基金
Development of a tumor-activated IL12 prodrug to treat solid tumors
开发肿瘤激活的 IL12 前药来治疗实体瘤
- 批准号:
10558656 - 财政年份:2021
- 资助金额:
$ 33.06万 - 项目类别:
Development of a tumor-activated IL12 prodrug to treat solid tumors
开发肿瘤激活的 IL12 前药来治疗实体瘤
- 批准号:
10374765 - 财政年份:2021
- 资助金额:
$ 33.06万 - 项目类别:
Development of a tumor-activated IL12 prodrug to treat solid tumors
开发肿瘤激活的 IL12 前药来治疗实体瘤
- 批准号:
10152759 - 财政年份:2021
- 资助金额:
$ 33.06万 - 项目类别:
Immunobiology and Immune Therapy for Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
9906874 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
默克尔细胞癌的免疫生物学和免疫治疗
- 批准号:
10380816 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别: